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Abstract 
Background: Immune checkpoint inhibitors have revolutionized the treatment paradigm of highly lethal malig-
nancies like advanced non-small cell lung cancer (NSCLC), demonstrating long-term tumour control and extended 
patient survival. Unfortunately, only 25–30% of patients experience a durable benefit, while the vast majority dem-
onstrate primary or acquired resistance. Recently, indoleamine 2,3-dioxygenase (IDO) activity has been proposed as a 
possible mechanism of resistance to anti-PD-1 treatment leading to an immunosuppressive microenvironment.
Methods: Pre-treatment serum concentrations of tryptophan (trp) and kynurenine (kyn) were measured by 
high-performance liquid chromatography tandem mass spectrometry in NSCLC patients treated with second-line 
nivolumab. The IDO activity was expressed with kyn/trp ratio. The associations between kyn/trp ratio and early 
progression, performance status (PS), age, sex, brain metastases, pleural effusion, progression free survival (PFS) and 
overall survival (OS) were analyzed using Spearman test and Mann–Whitney test.
Results: Twenty-six NSCLC patients were included in our study; 14 of them (54%) presented early progression 
(< 3 months) to nivolumab treatment. The median value of kyn/trp ratio was 0.06 µg/ml and the median value of qui-
nolinic acid was 68.45 ng/ml. A significant correlation between early progression and higher kyn/trp ratio and quino-
linic acid concentration was observed (p = 0.017 and p = 0.005, respectively). Patients presenting lower values of kyn/
trp ratio and quinolinic acid levels showed longer PFS (median PFS not reached versus 3 months; HR: 0.3; p = 0.018) 
and OS (median OS not reached vs 3 months; HR: 0.18; p = 0.0005).
Conclusion: IDO activity, expressed as kyn/trp ratio, is associated with response to immunotherapy; in particular, 
higher kyn/trp ratio could predict resistance to anti-PD-1 treatment. These preliminary results suggest the possibility 
of using anti-PD-1 plus IDO inhibitor in those patients with high level of kyn/trp ratio.
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Background
In NSCLC, nivolumab showed a long-term benefit in a 
significant proportion of pretreated patients with 2-year 
overall survival (OS) of 23 and 29% in squamous and non-
squamous histology, respectively, over-performing stand-
ard chemotherapy [1, 2]. However, more than two-thirds 
of NSCLC patients demonstrate primary or acquired 
resistance to PD-1 inhibition resulting in treatment 
failure [3]. Moreover, recent evidence suggested the exist-
ence of a novel pattern of disease progression referred 
to as hyper-progressive and characterized by a two-fold 
increase in tumour burden at first instrumental assess-
ment following anti-PD-1 treatment and very poor OS 
[4]. Therefore, there is an urgent need for biomarkers able 
to predict treatment responsiveness and to identify those 
patients unlikely to respond to PD-1 blockade in order to 
candidate them to different treatment approaches. While 
some predictive factors of response to immune check-
point inhibitors (ICI) have been proposed, among which 
PD-L1 expression/amplification, high tumor mutational 
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biomarkers for treatment resistance are still lacking [3]. 
Indoleamine 2,3-dioxygenase (IDO) is a key enzyme cata-
lyzing the first and rate-limiting step along the kynure-
nine (kyn) pathway of tryptophan (trp) metabolism 
outside the liver, which converts the essential amino 
acid l-trp to the main metabolite kyn [5]. Indoleamine 
2,3-dioxygenase has been shown to act as immune check-
point involved in peripheral immune tolerance since it is 
able to inhibit T-cells proliferation by starving them from 
trp to sensitize T-cells to apoptosis [6–11]. In NSCLC, 
augmented trp catabolism, resulting in higher kyn serum 
concentration, has been linked to more advanced stage at 
diagnosis, poorer prognosis and to a lesser likelihood of 
response to chemotherapy [12–14]. More interestingly, 
growing preclinical evidence suggests that increase in 
IDO activity can be involved in resistance to checkpoint 
inhibition [15] In the present study, we aimed to inves-
tigate whether IDO activity, expressed as kyn/trp ratio, 
can inform about response to nivolumab, particularly 
identifying those patients resistant to PD-1 blockade in a 
cohort of previously treated NSCLC.
Methods
Patients
Patients with stage IV NSCLC followed at our Institution 
from June 2016 to July 2017 were enrolled onto this ret-
rospectively study. Inclusion criteria were: age > 18 years; 
histologically-documented diagnosis of NSCLN; Eastern 
Cooperative Oncology Group (ECOG) performance sta-
tus ≤ 2; second-line treatment with anti-PD-1 nivolumab; 
adequate cardiac, pulmonary, renal, liver and bone mar-
row function; written informed consent. Exclusion 
criteria were: autoimmune disease; symptomatic inter-
stitial lung disease and any other significant comorbid-
ity; systemic immunosuppression; prior treatment with 
immune-stimulatory antitumor agents including check-
point-targeted agents.
Nivolumab treatment was administered at a standard 
dose of 3 mg/kg every 2 weeks until disease progression 
or development of unacceptable toxicity. Radiological 
response was assessed with i-RECIST Criteria and clas-
sified according to disease control (complete response, 
partial response and stable disease) and progressive dis-
ease. All toxicity was graded according to the National 
Cancer Institute Common Terminology Criteria for 
Adverse Events (version 4.0) and toxicity assessments 
performed at day 1 of every cycle until the end of treat-
ment. Progression-free survival (PFS) was defined as the 
time from patient registration on clinical trial until the 
first documented tumour progression or death from any 
cause. Overall survival (OS) was defined as the time from 
patient registration to death from any cause.
We defined as early progressors, patients experienc-
ing disease progression within three months from the 
beginning of nivolumab. The study was conducted in 
accordance with good clinical practice guidelines and the 
declaration of Helsinki. The final version of the protocol 
was approved by the Institutional Ethics Committee.
Kynurenine analysis
We evaluated serum levels of trp, kyn, and quinolinic 
acid by a modified liquid chromatography–tandem mass 
spectrometry (LC–MS/MS) method, [ADHD]. Serum 
samples were collected and stored at − 80 °C until analy-
sis. Fifty μl of serum samples were deproteinized using 
50 μl of Internal Standard (IS) solution (50 µM in TCA 
4%), vortex-mixed and centrifuged at 14,000  rpm for 
15  min. Twenty μl of clean upper layer were injected 
into chromatographic system. Chromatographic separa-
tion of analytes was performed using an Agilent Liquid 
Chromatography System series 1100 (Agilent Technolo-
gies, USA), on a biphenyl column (100 × 2.1  mm, Kine-
tex 2.6  μm Biphenyl, 100 Å, Phenomenex, CA, USA) 
equipped with a security guard precolumn (Phenomenex, 
Torrance, CA, USA). The mobile phase consisted of a 
solution of 0.1% aqueous formic acid (A) and 100% meth-
anol (B); elution was performed at flow rate of 400  μl/
min, using an elution gradient. The mass spectrometry 
method was performed on a 3200 triple quadrupole sys-
tem Applied Biosystems, Foster City, CA, USA) equipped 
with a Turbo Ion Spray source. The detector was set in 
the positive ion mode. The instrument was set in the 
Multiple Reaction Monitoring (MRM) mode. Data were 
acquired and processed by the Analyst 1.5.1 Software.
Statistical analysis
In the descriptive analysis, quantitative variables were 
described as mean and range, while qualitative variables 
as number and percentage.
PFS and OS were estimated using the Kaplan–Meier 
method, comparison between groups were made using 
the log-rank test, and Mantel-Cox method was used to 
generate hazard ratios (HRs) and 95% confidence inter-
vals (CIs).
Correlation was estimated using Spearman’s rho and 
comparison was evaluated using the nonparametric 
Mann–Whitney U test.
To determinate factors associated with early progres-
sors, multivariate logistic regression models were used. 
Results of multivariate analysis were expressed in odds 
ratio and 95% CIs. Statistical significance was set at 
p < 0.05. Statistical analyses were performed using IBM 
SPSS Statistics for Window Version 23.0 (Armonk, NY, 
USA) or GraphPad Prism (GraphPad, Inc, San Diego, 
CA, USA).
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Results
Clinical characteristics
Twenty-six stage IV NSCLC patients treated with sec-
ond-line nivolumab were enrolled in this study. Base-
line clinicopathological characteristics of patients are 
summarized in Table  1. Among them, 19 patients had 
squamous-cell carcinoma and the remaining had non-
squamous histology (6 adenocarcinoma and 1 undiffer-
entiated tumour). Twenty patients were male (76.9%), 
and median age was 65 years. The median value of kyn/
trp was 0.06 µg/ml and median value of quinolinic acid 
was 68.45 ng/ml.
Correlation of serum kyn/trp ratio and quinolinic acid 
concentration with immunotherapy response
With a median follow up of 6.9 months, 7 (27%), 5 (19%) 
and 14 (54%) patients had a stable disease (SD), a partial 
response (PR) and a progressive disease (PD), respec-
tively, according to i-RECIST v1.1 criteria. All patients 
were assessed at baseline for serum trp, kyn and qui-
nolinic acid levels. Patients who showed an early pro-
gression (within 3  months) to nivolumab (n = 14) had a 
significantly higher concentration of kyn/trp ratio than 
others (0.09 vs 0.05, respectively, p = 0.01) as well as a 
higher quinolinic acid level (121,15 vs 55,12, respectively, 
p = 0.01) (Fig. 1).
On multivariate analysis (Table  2), kyn/trp ratio was 
significant associated with early progression (p = 0.01). 
We observed a significant correlation only between early 
progression and kyn/trp ratio and quinolinic acid con-
centration (respectively p = 0.017 and p = 0.005).
Correlation of serum kyn/trp ratio and quinolinic acid 
concentration with survival
Median PFS was 4  months and median OS was 
6.5 months in the whole cohort.
Patients were stratified by median value of serum 
kyn/trp value (0.06  µg/ml) and of serum quinolinic 
acid concentration (68.45  ng/ml). PFS was signifi-
cantly longer in patients presenting lower values of 
kyn/trp than in patients showing higher values of kyn/
trp (median PFS not reached versus 3  months; HR: 
0.2; 95% CI 0.06–0.62; p = 0.001). Similar results were 
Table 1 Main baseline characteristics of  the  study 
population
N (%) Serum kyn/
trp ratio (µg/
ml)




 < 65 11 (42.3) 0.06 ± 0.03 74.47 ± 45.93
 65+ 15 (57.7) 0.08 ± 0.05 102.55 ± 72.99
Sex
 Male 20 (76.9) 0.08 ± 0.04 99.21 ± 69.37
 Female 6 (23.1) 0.05 ± 0.02 62.22 ± 24.24
Histology
 Adenocarcinoma 6 (23.1) 0.09 ± 0.04 127.85 ± 59.78
 Squamous-cell 
carcinoma
19 (73.1) 0.07 ± 0.04 79.69 ± 63.25
 Undifferentiated 
tumor
1 (3.8) 0.04 76.2
ECOG PS
 0–1 25 (96.2) 0.07 ± 0.03 88.26 ± 63.54
 > 1 1 (3.8) 0.18 151
Cerebral metastasis
 Yes 3 (11.5) 0.05 ± 0.04 91.54 ± 64.77
 No 23 (88.5) 0.08 ± 0.04 84.03 ± 64.14
Pleural effusion
 Yes 6 (23.1) 0.07 ± 0.04 79.24 ± 45.54
 No 20 (76.9) 0.09 ± 0.05 110.39 ± 99.95
Early progressor
 Yes 14 (53.8) 0.09 ± 0.05 121.15 ± 72.34
 No 12 (46.2) 0.05 ± 0.01 55.12 ± 20.18
Fig. 1 Correlation of serum kyn/trp ratio and serum quinolic acid concentration with immunotherapy response. Patients who showed an early 
progression (YES, n = 14) present a significantly higher concentration of kyn/trp ratio (a) and quinolic acid concentration (b) compared to patients 
who do not have an early progression (NO, n = 12). #p < 0.05 (Mann–Whitney test)
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observed in patient stratified by quinolinic acid val-
ues (median PFS not reached versus median 3 months; 
HR: 0.3; CI 0.1–0.9; p = 0.018) (Fig. 2a).
Patients with a lower kyn/trp ratio value showed 
even a significantly better OS compared with patients 
with a higher kyn/trp ratio value (median OS not 
reached versus median 3  months; HR 0.18; 95% CI 
0.06–0.56; p = 0.0005). Similar results were observed 
in patient stratified by quinolinic acid values (median 
OS not reached versus median 3 months; HR 0.2; 95% 
CI 0.06–0.660; p = 0.0077) (Fig. 2b).
Discussion
In our preliminary analysis we found that baseline serum 
kyn/trp ratio, expression of IDO activity, could repre-
sent both a prognostic and predictive value in advanced 
NSCLC patients treated with second-line nivolumab. In 
fact, lower baseline level of kyn/trp ratio were signifi-
cantly associated with better PFS and OS in our cohort. 
More interestingly and conversely, higher level of kyn/
trp ratio correlated with early progression retaining an 
independent statistically significant value in multivariate 
analysis. In this study, patients were selected in accord-
ance with eligibility criteria from registrative clinical tri-
als of nivolumab in pretreated NSCLC (CheckMate 017 
and CheckMate 057) and median PFS was consistent 
with historical data reported in the literature [16, 17].
Given the evidence that only a minority of cancer 
patients can benefit from ICI, a large amount of research 
is currently focused on defining predictive biomarkers 
able to select responsive or resistant patients in order to 
maximize the cost-effectiveness of treatment.
Over last few years, several predictive factors have 
been proposed that rely on patients’ characteristics as 
well as tumour and microenvironment profiles. PD-L1, 
which is expressed both on tumour and inflammatory 
cells, is arguably the most extensively studied biomarker 
for ICIs responsiveness, although it has showed some 
limitations [3]. More recently, the understanding of the 
Table 2 Multivariate analysis: association between patiens 
characteristics and early progression
p value Odds ratio (95% CI)
Cerebral metastasis 0.48 3.18 (0.12–81.69)
Pleural effusion 0.66 0.53 (0.33–8.71)
ECOG PS 0.39 2.58 (0.92–22.75)
Serum kyn/trp 0.01 0.01 (0.00–0.41)
Serum quinolic acid 0.81 1.38 (0.09–20.30)
Fig. 2 Correlation of serum kyn/trp ratio and quinolonic acid concentration with survival. Progression free survival (PFS, a) and overall survival (OS, 
b) were addressed by the Kaplan–Meier method and log-rank test
Page 5 of 6Botticelli et al. J Transl Med  (2018) 16:219 
correlation of microsatellite instability status with immu-
notherapy response has led to the FDA cancer site/histol-
ogy-agnostic approval of the anti-PD-1 pembrolizumab 
[18]. Accordingly, tumour mutational burden (TMB) and 
mRNA profile are being considered promising response 
indicators [19]. In particular TMB has been used to select 
patients in CHECKMATE 227 trial, demonstrating a 
benefit of immunotherapy in patients with mutational 
load higher than 10 mutations per megabase. Regarding 
circulating biomarkers, some encouraging results have 
been reported for IL 8 [20] and circulating T lympho-
cytes [21]. However, all these putative biomarkers have 
strong limitations and they have not shown clinical use-
fulness for the different settings.
In this context, IDO has been identified as a marker of 
activation of immunological pathways induced by IFN-
gamma, representing one of the main immune escape 
mechanism of tumor cells. IDO activity would also 
appear as negative prognostic factor in stage III-IV lung 
cancer [22–27].
Furthermore, Allison et  al. demonstrated that IDO 
knockout mice treated with anti CTLA-4, anti PD-1 or 
anti GITR presented delay in B16 melanoma tumour 
growth and increased OS compared with wild-type 
mice [28]. Notably, tissue expression of IDO has been 
lately associated with a better response to nivolumab in 
patients with renal cell carcinoma [29].
Our preliminary results showed that kyn/trp ratio 
serum levels are statistically higher in early progressors 
allowing to identify a proportion of NSCLC patients with 
intrinsic resistance to anti PD-1, and with a poor progno-
sis both in terms of PFS and OS. In particular, the median 
PFS of the whole cohort is not reached, while the median 
PFS of “high kyn/trp ratio patients “was 3 months, very 
similar to that of hyperprogressive patients from the 
study by Champiat et al. [4]. Interestingly, in our cohort, 
the IDO activity does not seem to be correlated with 
clinical parameters such as brain metastases, pleural effu-
sion, age and ECOG PS.
Moreover, quinolinic acid levels are strongly associated 
with response to nivolumab in our study. Quinolinic acid 
reflects the metabolism of kynurenine and it is involved 
in tumour progression not only diminishing immune 
activation but also increasing the synthesis of NAD, 
through quinolinic acid phosphoribosyltransferase, that 
is necessary to prevent apoptosis of neoplastic cells [30].
Our findings suggest a possible role to IDO in medi-
ating resistance to anti PD-1 agents and provide a 
rationale for an early administration of anti-IDO com-
pounds in those patients with high baseline kyn/trp 
ratio or high quinolinic acid levels. In fact, patient 
selection based on this biomarker could most probably 
avoid negative results of clinical trials designed without 
considering the immunological background of patients, 
i.e. the extent of the immunosuppressive milieu.
Conclusion
In conclusion we found that the kyn/trp ratio and qui-
nolinic acid level in the peripheral blood of NSCLC 
patients may be a potential predictive biomarker of 
resistance to anti-PD-1. The kyn/trp ratio and quino-
linic acid are associated with early progression, PFS and 
OS. Despite the small sample, our study suggests that 
IDO could represent an easy-assessable and cost-effec-
tive biomarker particularly useful in identifying patients 
more likely to have a benefit with a combination of anti-
PD-1 and anti-IDO. Future clinical trials are warranted 
to confirm its role as predictive biomarkers as well as 
therapeutic target, introducing immuno-oncology in 
the scenario of precision immuno-oncology.
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